The FDA approved oral semaglutide to reduce the risk of major adverse cardiovascular events (MACE) in patients with type 2 diabetes (T2D).
Nataly Estrin, PharmD, MBA, CSP
Advertisement
Articles by Nataly Estrin, PharmD, MBA, CSP
Advertisement
Latest Updated Articles
Oral Semaglutide Approved to Reduce the Risk of Cardiovascular EventsPublished: January 17th 2026 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
TrumpRx Launches, Offering Cash-Paying Patients Discounted Drugs
2
SGLT2 Inhibitors in T2D Lower 5-Year Risk of CKD and Acute Kidney Injury
3
Pharmacist Takeover: CAR T Therapy Signals a Shift in ALL Treatment
4
Balancing Survival and Quality of Life in Pancreatic Cancer: Expert Perspectives From an Immuneering Panel
5